BIOA
Drug Manufacturers - Specialty & Generic · Healthcare
Equibles does not estimate personal net worth.
Get an email with a short summary when BioAge Labs, Inc. publishes a filing, an earnings call transcript or a press release.
Get BIOA alertsThe proxy statement of BioAge Labs, Inc. reports total compensation of $1,476,080 for Paul Rubin in fiscal 2025, including a base salary of $520,200. Disclosed compensation is on record for 3 fiscal years. Paul Rubin has spoken on 1 earnings call across 1 company, most recently for BioAge Labs, Inc. on April 21, 2026. BioAge Labs, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at BioAge Labs, Inc. includes Kristen Fortney (CEO), Dov Goldstein (CFO) and Eric Morgen (COO).
“I'll start with the overall trial design and key objectives, and then I'll move into the detailed results. Next slide.”
Proxy statement
Start not stated–present
Last confirmed April 21, 2026
BIOA
Drug Manufacturers - Specialty & Generic · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | BioAge Labs, Inc. (BIOA) | Chief Medical Officer | $520,200 | $1,476,080 |
| 2024 | BioAge Labs, Inc. (BIOA) | Chief Medical Officer | $488,139 | $1,923,841 |
| 2023 | BioAge Labs, Inc. (BIOA) | Chief Medical Officer | $468,939 | $836,762 |